<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18175">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01726010</url>
  </required_header>
  <id_info>
    <org_study_id>102012</org_study_id>
    <nct_id>NCT01726010</nct_id>
  </id_info>
  <brief_title>22-G-Procore Needle for the Diagnosis of SETs of the Upper GI Tract</brief_title>
  <acronym>PRO-SET</acronym>
  <official_title>Endoscopic Ultrasound Guided Biopsy of Subepithelial Tumors of the Upper Gastrointestinal Tract Using the 22-G-Procore Needle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this prospective study is to evaluate the feasibility of the 22-G Core Biopsy
      Needle with reverse bevel (Procore TM) in biopsy sampling of subepithelial tumors of the
      upper gastrointestinal tract.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>diagnostic yield</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with adequate tissue sample (which allows definitive diagnosis)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Subepithelial Tumors of the Upper Gastrointestinal Tract</condition>
  <arm_group>
    <arm_group_label>22-G Procore Needle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>22-G Procore Needle</intervention_name>
    <arm_group_label>22-G Procore Needle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient age 18 years and older

          2. All patients with subepithelial tumors of the upper GI tract (maximum size: 3 cm)

        Exclusion Criteria:

          1. Unable to obtain informed consent

          2. ASA class 4 or 5

          3. known pregnancy

          4. contraindication endoscopy

          5. contraindication for taking biopsies
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Klinikum rechts der Isar</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan von Delius, MD</last_name>
      <email>stefan_ruckert@yahoo.de</email>
    </contact>
    <contact_backup>
      <last_name>Christoph Schlag, MD</last_name>
      <email>Christoph.Schlag@lrz.tum.de</email>
    </contact_backup>
    <investigator>
      <last_name>Stefan von Delius, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph Schlag, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gregor Weirich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <lastchanged_date>November 8, 2012</lastchanged_date>
  <firstreceived_date>November 4, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
